Over the last decade, the approach to strategic management of Drug Development has been progressively rationalised, in parallel to the development of financial and risk analysis quantitative models. This book examines the evolution of R&D risk-adjusted models, arguing that financial evaluation has progressively moving away from deterministic quantitative analysis, in favour of non-linear, stochastic algorithms.The relentless quest for capturing the value of Pharmaceutical Research will demand for a new emphasis on integration among disciplines and models. The application of risk adjusted evaluation models to earlier stages of the discovery process is an important area for further research and value creation.
Troubled economic times are putting an extraordinary pressure on corporate managers, who have to make investment decisions under unprecedented uncertainty and risk. The aim of this book is to help managers to reflect upon the critical assumptions underlying the most relevant tools for valuation of corporate investments under uncertainty. It offers a wide range of working papers, journal articles and case studies which are the fruit of our recent experience in teaching, consulting and research. This book is ideally suited to both managers and MBA students who seek to improve their critical ability to make value decisions based on an array of relevant investment valuation tools.
Troubled economic times are putting an extraordinary pressure on corporate managers, who have to make investment decisions under unprecedented uncertainty and risk. The aim of this book is to help managers to reflect upon the critical assumptions underlying the most relevant tools for valuation of corporate investments under uncertainty. It offers a wide range of working papers, journal articles and case studies which are the fruit of our recent experience in teaching, consulting and research. This book is ideally suited to both managers and MBA students who seek to improve their critical ability to make value decisions based on an array of relevant investment valuation tools.
Over the last decade, the approach to strategic management of Drug Development has been progressively rationalised, in parallel to the development of financial and risk analysis quantitative models. This book examines the evolution of R&D risk-adjusted models, arguing that financial evaluation has progressively moving away from deterministic quantitative analysis, in favour of non-linear, stochastic algorithms.The relentless quest for capturing the value of Pharmaceutical Research will demand for a new emphasis on integration among disciplines and models. The application of risk adjusted evaluation models to earlier stages of the discovery process is an important area for further research and value creation.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.